{"schema":"hottub-news/story/v1","story":"st_3fql2tu6i4ezck7fz7ya","title":"HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer","title_en":null,"outlets":3,"brief":null,"page":"https://hottub.news/stories/hutchmed-announces-submission-of-us-nda-for-orpathys-plus-tagrisso-in-3fql2tu6i4","count":3,"items":[{"id":"n_74mvofc4yjtldp5ie75a","seq":575858,"kind":"article","title":"HUTCHMED Seeks FDA Approval For ORPATHYS-TAGRISSO In Resistant Lung Cancer","url":"https://www.rttnews.com/3694523/hutchmed-seeks-fda-approval-for-orpathys-tagrisso-in-resistant-lung-cancer.aspx","published":"2026-09-29T03:56:00Z","seen":"2026-09-29T04:20:14Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["business","politics","health","economy"],"entities":[{"id":"Q113510355","name":"Hutchison MediPharma Limited","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"story":"st_3fql2tu6i4ezck7fz7ya","category":"health","category_p":0.5699999928474426,"sentiment":"neutral","tone":-0.07000000029802322,"political":0.3400000035762787},{"id":"n_wdjnjte2pqofirsl4mfa","seq":555223,"kind":"article","title":"HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer","url":"https://www.manilatimes.net/2026/09/29/tmt-newswire/globenewswire/hutchmed-announces-submission-of-us-nda-for-orpathys-plus-tagrisso-in-met-driven-egfr-mutated-lung-cancer/2434594","published":"2026-09-29T00:03:00Z","seen":"2026-09-29T01:37:58Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","politics","business","health"],"entities":[{"id":"Q113510355","name":"Hutchison MediPharma Limited","type":"org"},{"id":"Q29006526","name":"Tagrisso","type":"other"}],"story":"st_3fql2tu6i4ezck7fz7ya","category":"health","category_p":0.6299999952316284,"sentiment":"neutral","tone":-0.019999999552965164,"political":0.1599999964237213},{"id":"n_3fql2tu6i4ezck7fz7ya","seq":546401,"kind":"press_release","title":"HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer","url":"https://www.globenewswire.com/news-release/2026/09/29/3370345/0/en/hutchmed-announces-submission-of-us-nda-for-orpathys-plus-tagrisso-in-met-driven-egfr-mutated-lung-cancer.html","summary":"— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —","published":"2026-09-29T00:00:00Z","seen":"2026-09-29T00:06:23Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:hcm","hkse:0013","lse:hcm","us44842l1035","kyg4672n1198"],"entities":[{"id":"Q113510355","name":"Hutchison MediPharma Limited","type":"org"},{"id":"Q29006526","name":"Tagrisso","type":"other"},{"id":"Q14865565","name":"EGFR","type":"other"}],"mentions":2,"story":"st_3fql2tu6i4ezck7fz7ya","category":"health","category_p":0.6299999952316284,"sentiment":"neutral","tone":0.20000000298023224,"political":0.1599999964237213}]}